ImportRefusal LogoImportRefusal

LABORATE PHARMACEUTICAL INDIA

⚠️ High Risk

FEI: 3012573136 • HARANA • INDIA

FEI

FEI Number

3012573136

📍

Location

HARANA

🇮🇳

Country

INDIA
🏢

Address

E-11 INDUSTRIAL AREA, , HARANA, , India

High Risk

FDA Import Risk Assessment

62.5
LowModerateHighCritical

This firm has a significant history of FDA import refusals with notable violations.

Statistics

5
Total Refusals
3
Unique Violations
11/19/2025
Latest Refusal
10/10/2024
Earliest Refusal

Score Breakdown

Violation Severity
75.0×40%
Refusal Volume
28.8×30%
Recency
96.8×20%
Frequency
45.1×10%
How is this score calculated?

Proprietary Algorithm

  • 40% Violation Severity — AI-assessed (1-10)
  • 30% Refusal Volume — Logarithmic scale
  • 20% Recency — Decays over 5 years
  • 10% Frequency — Refusals per year

© ImportRefusal.com Original Analysis

Violation Summary

755×

UNAPPROVED

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).

1182×

NOT LISTED

It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).

32801×

FRNMFGREG

The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. It appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.

Refusal History

DateProductViolationsDivision
11/19/2025
66XCY06HOMEOPATHIC RESPIRATORY
75UNAPPROVED
Division of Southeast Imports (DSEI)
3/4/2025
60LDA99ANALGESIC, N.E.C.
118NOT LISTED
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/8/2025
62LDY09TINIDAZOLE (ANTI-PROTOZOAL, A-LEISHMANIAL, A-MALARIAL)
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/8/2025
61FDY24CLOXYQUIN (ANTI-BACTERIAL) (NOT ANTIBIOTIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
10/10/2024
61ACK06CHLOROQUINE PHOSPHATE (ANTI-AMEBIC)
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Southeast Imports (DSEI)

Frequently Asked Questions

What is LABORATE PHARMACEUTICAL INDIA's FDA import refusal history?

LABORATE PHARMACEUTICAL INDIA (FEI: 3012573136) has 5 FDA import refusal record(s) in our database, spanning from 10/10/2024 to 11/19/2025.

What is an FEI number?

FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. LABORATE PHARMACEUTICAL INDIA's FEI number is 3012573136.

What types of violations has LABORATE PHARMACEUTICAL INDIA received?

LABORATE PHARMACEUTICAL INDIA has been cited for 3 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.

Where does this information about LABORATE PHARMACEUTICAL INDIA come from?

All FDA import refusal data for LABORATE PHARMACEUTICAL INDIA is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.

Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.